STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Wolters Kluwer appoints Greg Samios as CEO of Health division

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Wolters Kluwer (WTKWY) has appointed Greg Samios as the new CEO of its Health division, effective June 1, 2025. Samios, who brings over 25 years of healthcare experience, succeeds Stacey Caywood, who became a Member of the Executive Board on May 15, 2025.

As Executive Vice President of the Health division's largest business units, Samios has led growth in clinical decision support products like UpToDate and Medi-Span. He spearheaded the integration of generative AI into healthcare products and strengthened partnerships with digital health companies. His previous roles include Executive VP of Legal & Regulatory U.S. at Wolters Kluwer and health-focused positions at Elsevier.

Loading...
Loading translation...

Positive

  • Appointment of an experienced internal candidate with 25+ years of healthcare expertise
  • Track record of driving growth in key products (UpToDate and Medi-Span)
  • Experience in implementing generative AI solutions in healthcare products
  • Strong background in both health and legal sectors within Wolters Kluwer

Negative

  • None.

PRESS RELEASE

Wolters Kluwer appoints Greg Samios as CEO of Health division

Experienced healthcare executive has track record of driving innovation and delivering results

Alphen aan den Rijn May 29, 2025 — Wolters Kluwer, a global leader in information solutions, software, and services for professionals, has named Greg Samios as Chief Executive Officer of its Health division, effective June 1. Samios succeeds Stacey Caywood, who became a Member of the Executive Board of Wolters Kluwer on May 15, 2025.  

A seasoned healthcare executive with more than twenty-five years of experience, Samios has served as Executive Vice President of the Health division’s two largest business units, Clinical Effectiveness and Health Learning, Research, and Practice. While a Health division leader, Samios has driven growth in Wolters Kluwer’s leading clinical decision support and clinical drug information products, UpToDate and Medi-Span. He also led the introduction of generative AI into the company’s healthcare products and solidified partnerships with leading digital health companies.

In a prior role at Wolters Kluwer, Samios served as Executive Vice President of the Legal & Regulatory U.S. business. His career experience before joining Wolters Kluwer included several health-focused positions at Elsevier spanning more than ten years. He earned a Master of Business Administration from Duke University Fuqua School of Business and graduated with a B.S. and M.S. in Engineering from the University of Rochester. 

“We are delighted to name Greg Samios as the new CEO of Wolters Kluwer Health,” said Nancy McKinstry, Chief Executive Officer and Chair of the Executive Board for Wolters Kluwer. “Our large, global Health division requires an experienced leader to continue driving innovation and adapting to market challenges. We are confident that Greg has the right combination of experience and passion to deliver on our strategy and drive incremental value for our customers and growth for our business.” 

Wolters Kluwer Health supports professionals across healthcare with trusted advanced technology, evidence-based solutions, research, and life-long learning. 

###
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Media Investor/Analyst
Stefan Kloet Meg Geldens
Associate Director Vice President
Global Communications Investor Relations
press@wolterskluwer.com ir@wolterskluwer.com
t: +316 1233 657  
   
Andre Rebelo  
Wolters Kluwer Health  
Director, External Communications  
andre.rebelo@wolterskluwer.com  
t: +1 781 392 2411  
   

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment


FAQ

Who is the new CEO of Wolters Kluwer Health division?

Greg Samios has been appointed as the new CEO of Wolters Kluwer Health division, effective June 1, 2025.

What is Greg Samios' experience before becoming WTKWY Health division CEO?

Samios has over 25 years of healthcare experience, served as Executive VP of Health division's largest units, led Legal & Regulatory U.S. at Wolters Kluwer, and held health-focused positions at Elsevier for over 10 years.

What are Greg Samios' key achievements at Wolters Kluwer Health?

He drove growth in UpToDate and Medi-Span products, led the introduction of generative AI into healthcare products, and established partnerships with digital health companies.

Who did Greg Samios replace as CEO of WTKWY Health division?

Greg Samios succeeds Stacey Caywood, who became a Member of the Executive Board of Wolters Kluwer on May 15, 2025.
Wolters Kluwer N V

OTC:WTKWY

WTKWY Rankings

WTKWY Latest News

WTKWY Stock Data

28.84B
234.37M
0.11%
Specialty Business Services
Industrials
Link
Netherlands
Alphen aan den Rijn